www.fdanews.com/articles/202966-astrazenecas-tagrisso-nabs-eu-approval-for-early-stage-lung-cancer
AstraZeneca’s Tagrisso Nabs EU Approval for Early-Stage Lung Cancer
June 1, 2021
The European Commission has authorized AstraZeneca’s blockbuster Tagrisso (osimertinib) as an adjuvant treatment for adult patients with early-stage epidermal growth-factor receptor-mutated nonsmall-cell lung cancer following complete tumor removal.
The approval was supported by results from a late-stage trial in which Tagrisso significantly improved disease-free survival by lowering the risk of disease recurrence by 80 percent.
Approved to treat early-stage lung cancer in more than 50 countries, Tagrisso earned $4.3 billion in global sales last year, an increase of 36 percent from the previous year.